Publications by authors named "Jillian F Evans"
Article Synopsis
- Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease, and the current treatment with Rapamycin only slows its progression, emphasizing the need for new therapeutic options.
- Nitazoxanide (NTZ), a safe and approved drug for treating diarrhea, shows promise due to its mTORC1 inhibitory effect and potential for repurposing in LAM treatment.
- In experiments, NTZ effectively reduced cell growth at specific doses but did not inhibit mTORC1 as expected; it lowered pAkt levels, and while it showed some benefits in reducing lung lesions in mouse models, results need further analysis.
Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease caused by tuberous sclerosis complex 1/2 (TSC1/2) gene mutations in pulmonary mesenchymal cells, resulting in activation of the mechanistic target of rapamycin complex 1 (mTORC1). A subset of patients with LAM develop pulmonary vascular remodeling and pulmonary hypertension. Little, however, is known regarding how LAM cells communicate with endothelial cells (ECs) to trigger vascular remodeling.
View Article and Find Full Text PDF